Double-Drug attack on tough pancreatic cancer shows promise in small trial

This study tested a combination of two oral chemotherapy drugs, vemurafenib and sorafenib, in 10 people with advanced pancreatic cancer that has a specific genetic change called a KRAS mutation. All participants had already tried at least two standard treatments without success. The main goal was to see if the drug combination could control the cancer for at least 16 weeks. The approach targets a key signaling pathway in cancer cells.